Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007;46(11):771-4.
doi: 10.2169/internalmedicine.46.6262. Epub 2007 Jun 1.

Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease

Masashi Matsuyama  1 , Takeshi Suzuki, Hiroto Tsuboi, Satoshi Ito, Mizuko Mamura, Daisuke Goto, Isao Matsumoto, Akito Tsutsumi, Takayuki Sumida
Affiliations
Free article
Case Reports

Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease

Masashi Matsuyama et al. Intern Med. 2007.
Free article

Abstract

We report three cases of multicentric Castleman's disease (MCD) successfully treated with anti-interleukin-6 receptor antibody (tocilizumab). Tocilizumab was administered intravenously at a dose of 8 mg/kg every 2 weeks. In each case, tocilizumab alleviated symptoms, including generalized fatigue, pyrexia, and alleviated biochemical abnormalities, including anemia, hypoalbuminemia, hypergammaglobulinemia, and increased C-reactive protein (CRP). Side effects included hypercholesterolemia, acute pyelonephritis, mild inflammation of the parotid glands, and upper respiratory system inflammation. Other severe side effects were not observed. These results indicate that tocilizumab is effective for the treatment of MCD. This is the first report on tocilizumab efficacy for Castleman's disease after approval for use for Castleman's disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

MeSH terms